Well this played out exactly how I figured it. Outside of the obvious integration NRE cash flow associated with this subcontract, one can have some expectations for the future:
Phase III development award 'forthcoming' (lol I sound like JJ).
Aethlon's work must be meeting objectives to be included in the integration planning. At the end of integration and clinical trials, there is the likelihood of a govt purchase order and steady cash flow.
Also as a reminder, at current expense burn rates Aethlon was positive by $314K or so (from memory) last qtr. If expenses are held the same, Aethlon will continue to turn in positive qtrs. That should go a long way in terms of PPS gains in my opinion.
Hopefully we are getting some revenue on the HCV side.
Market Data 
Markets 
AI
